ReviewFrontiers in oral health2026
Platelet-rich fibrin as a therapeutic modality for oroantral communication closure: a systematic review and meta-analysis.
Review in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oroantral communication (OAC) is an abnormal connection between the oral cavity and maxillary sinus, often occurring after posterior maxillary tooth extraction. If untreated, OAC can progress to oroantral fistulas (OAFs), leading to chronic sinusitis and treatment failure. Platelet-rich fibrin (PRF), an autologous biomaterial with regenerative potential, has been proposed as a therapeutic option. This study aimed to evaluate the efficacy and safety of PRF in the closure of OACs/OAFs. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered with PROSPERO. A comprehensive literature search was conducted in April 2025 across Cochrane, PubMed, Google Scholar and Web of Science. Studies were selected using PICO criteria: patients with OACs/OAFs; PRF as a standalone or adjunct intervention; comparison to conventional treatments; outcome of successful closure; and human studies published in English or Arabic. Data extraction and risk of bias assessment were performed independently by multiple reviewers using Cochrane RoB 2, MINORS, and MMS tools. Meta-analysis was conducted using Review Manager software. Results: Nineteen studies including 442 patients were included. PRF demonstrated high closure rates, often within three weeks, with enhanced mucosal and bone healing. Minimal complications were reported. Although methodological heterogeneity and moderate-to-high risk of bias were observed, the overall findings support the beneficial role of PRF in OAC/OAF management, particularly in minor to moderate defects. Conclusion: PRF is a safe, effective, and minimally invasive adjunct for the closure of OACs/OAFs. Its application is associated with significantly reduced patient morbidity, including less pain, lower analgesic consumption, minimal swelling, and greater overall comfort. Furthermore, as a minimally invasive and entirely autologous material, PRF eliminates the risks of immunogenic reactions or disease transmission, while its application helps preserve critical anatomical structures like the buccal sulcus, which is essential for future prosthetic rehabilitation. Systematic Review Registration: PROSPERO CRD420251028634.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.